Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease

Study Overview
=================
Brief Summary
-----------------
Cancer is the most important acquired risk factor of thromboembolisms. More than 20% of all episodes of venous thromboembolism (VT) or pulmonary thromboembolisms (PT) are cancer related. Cancer patients with VT or PT are treated with low molecular weight heparins (LMWH) during at least 3 months, but nowadays the duration of treatment is not accurately determined. The D-Dimer determination has been used like recurrence predictors after LMWH treatment suspension, but in cancer patients the useful is limited. Phospholipid-dependent microparticles could been used like recurrence predictors in cancer patients and tailored the duration of LMWH treatment for each patient.

Detailed Description
-----------------
We are carrying out a study in Cancer-associated-thromboembolism patients in order to decide the suitable anticoagulation time. A set of exclusion criteria is being used to determine in which patients LMWH will be withdrawn. Patients are being followed after LMWH withdrawal until 6 months. Blood samples are being taken at baseline (LMWH withdrawal), 3 weeks and 3 months after. We will look for association between several biomarkers and venous thromboembolism recurrences.

Official Title
-----------------
Time of Treatment With Low Molecular Weight Heparins in Cancer Patients With Thromboembolic Disease. Procoagulant Role of Phospholipid-dependent Microparticles.

Conditions
-----------------
Cancer, Venous Thromboembolism, Pulmonary Thromboembolisms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with diagnosis of cancer (any) and diagnosis of pulmonary thromboembolism (PT) or venous thromboembolism (VT) , in treatment with low molecular weight heparin (LMWH). Patients treated with LMWH since cancer diagnostic. Signed informed consent sheet Exclusion Criteria: Patients with life expectancy lower than 6 months Pregnancy woman Patients with cerebral metastasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence thromboembolisms | Venous thromboembolisms or Pulmonary thromboembolism recurrence after LMWH suppression | 3 months | 
| Recurrence thromboembolisms | Venous thromboembolisms or Pulmonary thromboembolism recurrence after LMWH suppression | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemorrhagic events | Hemorrhagic events due to LMWH treatment | 6 months | 
| Thromboembolic event attributable death | Death related to embolic event | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Low molecular weight heparins, Procoagulants, Phospholipid-dependent Microparticles